Literature DB >> 12466347

Regulation of insulin-like growth factor binding protein-1 during protracted critical illness.

Dieter Mesotten1, Patric J D Delhanty, Frank Vanderhoydonc, Kevin V Hardman, Frank Weekers, Robert C Baxter, Greet Van Den Berghe.   

Abstract

IGF binding protein-1 (IGFBP-1), an important regulator of IGF bioavailability, has been shown to correlate with mortality in critically ill patients. In the liver, IGFBP-1 is transcriptionally repressed by insulin, and it is therefore a potential marker of hepatic insulin sensitivity. We have recently shown that, compared with conventional treatment, maintenance of normoglycemia with intensive insulin therapy decreased morbidity and mortality of continuously fed critically ill patients. This study compares the effect of conventional and intensive insulin therapy on IGFBP-1 and assesses its predictive value for mortality. In 363 patients who were dependent on intensive care for more than 7 d and were randomly assigned to either conventional or intensive insulin therapy, serum IGFBP-1 levels were measured on admission, on d 1, 8, 15, 22, and 29, and on the day of intensive care unit discharge or death. In addition, IGFBP-1 and phosphoenolpyruvate carboxykinase mRNA levels were measured by real-time RT-PCR in postmortem liver biopsies obtained from 74 patients who died in the intensive care unit. Although intensive insulin treatment lowered glycemia, it had no effect on IGFBP-1 serum levels. Instead, serum IGFBP-1 concentration was significantly higher in patients who ultimately died, and it differentiated nonsurvivors from survivors 3 wk before death. The predictive value of serum IGFBP-1 for mortality was similar to that of the APACHE-II score. Like circulating IGFBP-1, hepatic mRNA levels of IGFBP-1 and the similarly insulin-regulated gene, phosphoenolpyruvate carboxykinase, were not significantly different between conventional and intensive insulin therapy groups. These data suggest that hepatic insulin resistance in prolonged critically ill patients, reflected by high serum IGFBP-1 levels, is not overcome by intensive insulin therapy, and that this may affect patient outcome.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12466347     DOI: 10.1210/jc.2002-020664

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  23 in total

1.  Intensive versus conventional insulin therapy in type 2 diabetes patients undergoing D2 gastrectomy for gastric cancer: a randomized controlled trial.

Authors:  Shou-Gen Cao; Jian-An Ren; Bo Shen; Dong Chen; Yan-Bing Zhou; Jie-Shou Li
Journal:  World J Surg       Date:  2011-01       Impact factor: 3.352

2.  The pathogenesis of diclofenac induced immunoallergic hepatitis in a canine model of liver injury.

Authors:  Saravanakumar Selvaraj; Jung-Hwa Oh; Reinhard Spanel; Florian Länger; Hyoung-Yun Han; Eun-Hee Lee; Seokjoo Yoon; Jürgen Borlak
Journal:  Oncotarget       Date:  2017-09-23

Review 3.  Hyperglycemia in critical illness: a review.

Authors:  David Brealey; Mervyn Singer
Journal:  J Diabetes Sci Technol       Date:  2009-11-01

4.  The effect of insulin infusion upon protein metabolism in neonates on extracorporeal life support.

Authors:  Michael S D Agus; Patrick J Javid; Hannah G Piper; David Wypij; Christopher P Duggan; Daniel P Ryan; Tom Jaksic
Journal:  Ann Surg       Date:  2006-10       Impact factor: 12.969

5.  Effect of tight glucose control with insulin on the thyroid axis of critically ill children and its relation with outcome.

Authors:  Marijke Gielen; Dieter Mesotten; Pieter J Wouters; Lars Desmet; Dirk Vlasselaers; Ilse Vanhorebeek; Lies Langouche; Greet Van den Berghe
Journal:  J Clin Endocrinol Metab       Date:  2012-08-07       Impact factor: 5.958

6.  Intensive insulin therapy protects the endothelium of critically ill patients.

Authors:  Lies Langouche; Ilse Vanhorebeek; Dirk Vlasselaers; Sarah Vander Perre; Pieter J Wouters; Kristin Skogstrand; Troels K Hansen; Greet Van den Berghe
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

Review 7.  [Nutrition and immunonutrition in septic patients].

Authors:  K Mayer; M Schaefer; H Walmrath; F Grimminger; W Seeger
Journal:  Internist (Berl)       Date:  2006-04       Impact factor: 0.743

8.  Risk factors in critical illness myopathy during the early course of critical illness: a prospective observational study.

Authors:  Steffen Weber-Carstens; Maria Deja; Susanne Koch; Joachim Spranger; Florian Bubser; Klaus D Wernecke; Claudia D Spies; Simone Spuler; Didier Keh
Journal:  Crit Care       Date:  2010-06-18       Impact factor: 9.097

9.  Insulin-like growth factor-1 bioactivity plays a prosurvival role in older participants.

Authors:  Marcello Maggio; Chiara Cattabiani; Fulvio Lauretani; Stefania Bandinelli; Francesca De Vita; Elisabetta Dall'Aglio; Andrea Corsonello; Fabrizia Lattanzio; Giuseppe Paolisso; Luigi Ferrucci; Gian Paolo Ceda
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2013-05-13       Impact factor: 6.053

Review 10.  Stress-hyperglycemia, insulin and immunomodulation in sepsis.

Authors:  Paul E Marik; Murugan Raghavan
Journal:  Intensive Care Med       Date:  2004-02-26       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.